Drug Trial Radar · NCT04006808
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
184
Planned (sponsor's estimate)
Start
Oct 25, 2019
Primary completion
May 1, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant recipients aged 1-17 years
Conditions
- Herpes Zoster
Interventions
PED-HZ/suBiological
GSK's candidate vaccine- PED-HZ/su. is administered intramuscularly in the deltoid of the non-dominant arm, on a two-dose schedule in the two investigational groups.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects from the interventional groups, with solicited local adverse events (AEs)Time frame: Within 7 days after each vaccination (vaccines administered on day 1 and month 1)
- Number of subjects from the interventional groups, with solicited general AEsTime frame: Within 7 days after each vaccination (vaccines administered on day 1 and month 1)
- Number of subjects from the control groups with solicited general symptomsTime frame: Within 7 days after Visit Day 1
- Number of subjects from the control groups with solicited general symptomsTime frame: Within 7 days after Visit Month 1
- Number of subjects from the interventional groups with unsolicited AEs after each vaccinationTime frame: Within 30 days after each vaccination (vaccines administered on day 1 and month 1)
- Number of subjects from the control groups with unsolicited symptomsTime frame: Within 30 days after Visit Day 1
- Number of subjects from the control groups with unsolicited symptomsTime frame: Within 30 days after Visit Month 1
- Number of subjects with serious adverse events (SAEs), potential immune mediated diseases (pIMDs) and biopsy confirmed renal allograft rejection.Time frame: From Visit Day 1 up to Visit Month 2
- Number of subjects from the interventional groups with seizuresTime frame: Within 30 days after each vaccination (vaccines administered on day 1 and month 1)
- Number of subjects from the non-interventional groups with seizuresTime frame: Within 30 days after Visit Day 1
- Number of subjects from the non-interventional groups with seizuresTime frame: Within 30 days after Visit Month 1
- Number of subjects from the interventional groups with generalized convulsive seizuresTime frame: Within 7 days after each vaccination (vaccines administered on day 1 and month 1)
- Number of subjects from the non-interventional groups with generalized convulsive seizuresTime frame: Within 7 days after Visit Day 1
- Number of subjects from the non-interventional groups with generalized convulsive seizuresTime frame: Within 7 days after Visit Month 1
- Percentage of subjects with Anti-gE antibody concentrations in terms of Geometric Mean Concentrations (GMCs)Time frame: At Month 2 (one-month post-dose 2)
Locations
31 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Brussels, Belgium · Recruiting
GSK Investigational Site
Ghent, Belgium · Recruiting
GSK Investigational Site
Leuven, Belgium · Recruiting
GSK Investigational Site
Liège, Belgium · Recruiting
GSK Investigational Site
Bordeaux, France · Recruiting
GSK Investigational Site
Lille, France · Recruiting
GSK Investigational Site
Marseille, France · Recruiting
GSK Investigational Site
Montpellier, France · Recruiting
GSK Investigational Site
Nantes, France · Withdrawn
GSK Investigational Site
Paris, France · Recruiting
GSK Investigational Site
Paris, France · Recruiting
GSK Investigational Site
Toulouse, France · Recruiting
GSK Investigational Site
Genova, Italy · Completed
GSK Investigational Site
Milan, Italy · Recruiting
GSK Investigational Site
Padova, Italy · Recruiting
GSK Investigational Site
Roma, Italy · Recruiting
GSK Investigational Site
Torino, Italy · Recruiting
GSK Investigational Site
Gdansk, Poland · Recruiting
GSK Investigational Site
BaracaldoVizcaya, Spain · Recruiting
GSK Investigational Site
Espluges de Llobregat, Spain · Completed
GSK Investigational Site
HebrOn, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Seville, Spain · Recruiting
GSK Investigational Site
Birmingham, United Kingdom · Completed
GSK Investigational Site
Cardiff, United Kingdom · Completed
GSK Investigational Site
Glasgow Strathclyde, United Kingdom · Recruiting
GSK Investigational Site
London, United Kingdom · Recruiting
GSK Investigational Site
Manchester, United Kingdom · Recruiting
GSK Investigational Site
Nottingham, United Kingdom · Recruiting
GSK Investigational Site
Southampton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.